Sign in
Antifungal therapeutic drug monitoring practices: results of an Emerging Infections Network survey
Journal article   Open access   Peer reviewed

Antifungal therapeutic drug monitoring practices: results of an Emerging Infections Network survey

Kaitlin Benedict, Jeremy A W Gold, Susan E Beekmann, Philip M Polgreen, Mitsuru Toda and Dallas J Smith
Open forum infectious diseases, Vol.10(9), ofad468
09/2023
DOI: 10.1093/ofid/ofad468
PMCID: PMC10533201
PMID: 37771852
url
https://doi.org/10.1093/ofid/ofad468View
Published (Version of record) Open Access

Abstract

Abstract In a survey of 523 infectious disease specialists, a moderate-to-high percentage reported using any antifungal therapeutic drug monitoring (TDM) during itraconazole (72%), posaconazole (72%), and voriconazole (90%) treatment and low-to-moderate during prophylaxis (32%, 55%, and 65%, respectively). Long turnaround times for send-out TDM testing and logistical difficulties were frequent barriers.

Details

Metrics

Logo image